SG10201500957QA - Anti-nerve growth factor antibodies and methods of preparing and using the same - Google Patents
Anti-nerve growth factor antibodies and methods of preparing and using the sameInfo
- Publication number
- SG10201500957QA SG10201500957QA SG10201500957QA SG10201500957QA SG10201500957QA SG 10201500957Q A SG10201500957Q A SG 10201500957QA SG 10201500957Q A SG10201500957Q A SG 10201500957QA SG 10201500957Q A SG10201500957Q A SG 10201500957QA SG 10201500957Q A SG10201500957Q A SG 10201500957QA
- Authority
- SG
- Singapore
- Prior art keywords
- preparing
- methods
- same
- growth factor
- nerve growth
- Prior art date
Links
- 229940053128 nerve growth factor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483491P | 2011-05-06 | 2011-05-06 | |
| US201161531439P | 2011-09-06 | 2011-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500957QA true SG10201500957QA (en) | 2015-04-29 |
Family
ID=46168541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013081914A SG194795A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| SG10201500957QA SG10201500957QA (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013081914A SG194795A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20140170136A1 (es) |
| EP (2) | EP3502136A1 (es) |
| JP (2) | JP6181043B2 (es) |
| KR (1) | KR101833465B1 (es) |
| CN (1) | CN103764677A (es) |
| AU (1) | AU2012252153B2 (es) |
| BR (1) | BR112013028652A8 (es) |
| CA (1) | CA2834983C (es) |
| ES (1) | ES2704007T3 (es) |
| GB (1) | GB2504888B (es) |
| MY (1) | MY160884A (es) |
| RU (1) | RU2640252C2 (es) |
| SG (2) | SG194795A1 (es) |
| WO (1) | WO2012153123A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| KR101833465B1 (ko) * | 2011-05-06 | 2018-02-28 | 넥스베트 오스트레일리아 피티와이 리미티드 | 항신경 성장 인자 항체 및 그의 제조방법과 이용방법 |
| US10023636B2 (en) | 2013-12-20 | 2018-07-17 | Intervet Inc. | Caninized murine antibodies to human PD-1 |
| BR112017006203A2 (pt) | 2014-09-30 | 2018-05-02 | Intervet International B.V. | anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune. |
| CN104774265B (zh) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株 |
| CN104910274B (zh) * | 2015-02-12 | 2018-05-04 | 北京华安科创生物技术有限公司 | 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株 |
| TWI706959B (zh) * | 2015-05-22 | 2020-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＮＧＦ抗體Ｆａｂ片段 |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| JP2020531002A (ja) * | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用ｉｇｇ ｆｃ変異体 |
| GB2578867A (en) * | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| US10799289B2 (en) | 2018-10-15 | 2020-10-13 | Avent, Inc. | Compositions, systems, kits, and methods for neural ablation |
| WO2022087153A1 (en) * | 2020-10-22 | 2022-04-28 | Scout Bio, Inc. | Method of suppressing immune response to vector-delivered therapeutic protein |
| KR20240006586A (ko) | 2021-05-12 | 2024-01-15 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도 |
| CN118475612A (zh) | 2021-08-31 | 2024-08-09 | 斯科特生物公司 | 抗原结合分子及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| AU632843B2 (en) * | 1989-08-10 | 1993-01-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| AU2005243247B2 (en) * | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| WO2010027488A2 (en) * | 2008-09-04 | 2010-03-11 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| US8435523B2 (en) | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
| CA2791560A1 (en) * | 2010-03-04 | 2011-09-09 | Vet Therapeutics Inc. | Monoclonal antibodies directed to cd20 |
| BR112012022342A2 (pt) * | 2010-03-04 | 2017-02-14 | Vet Therapeutics Inc | anticorpos monoclonais dirigidos a cd52 |
| RS63063B1 (sr) * | 2010-08-19 | 2022-04-29 | Zoetis Belgium S A | Anti-ngf antitela i njihova upotreba |
| KR101833465B1 (ko) * | 2011-05-06 | 2018-02-28 | 넥스베트 오스트레일리아 피티와이 리미티드 | 항신경 성장 인자 항체 및 그의 제조방법과 이용방법 |
-
2012
- 2012-05-08 KR KR1020137032545A patent/KR101833465B1/ko active IP Right Grant
- 2012-05-08 AU AU2012252153A patent/AU2012252153B2/en active Active
- 2012-05-08 CN CN201280033623.8A patent/CN103764677A/zh active Pending
- 2012-05-08 MY MYPI2013702081A patent/MY160884A/en unknown
- 2012-05-08 GB GB1320050.6A patent/GB2504888B/en active Active
- 2012-05-08 EP EP18205439.5A patent/EP3502136A1/en not_active Withdrawn
- 2012-05-08 ES ES12723732T patent/ES2704007T3/es active Active
- 2012-05-08 BR BR112013028652A patent/BR112013028652A8/pt not_active Application Discontinuation
- 2012-05-08 SG SG2013081914A patent/SG194795A1/en unknown
- 2012-05-08 EP EP12723732.9A patent/EP2705056B1/en active Active
- 2012-05-08 US US14/115,772 patent/US20140170136A1/en not_active Abandoned
- 2012-05-08 WO PCT/GB2012/051004 patent/WO2012153123A1/en active Application Filing
- 2012-05-08 SG SG10201500957QA patent/SG10201500957QA/en unknown
- 2012-05-08 JP JP2014509819A patent/JP6181043B2/ja active Active
- 2012-05-08 RU RU2013154307A patent/RU2640252C2/ru not_active Application Discontinuation
- 2012-05-08 CA CA2834983A patent/CA2834983C/en active Active
-
2017
- 2017-04-05 JP JP2017075108A patent/JP6526089B2/ja active Active
-
2018
- 2018-09-12 US US16/129,674 patent/US20190276525A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6181043B2 (ja) | 2017-08-16 |
| US20190276525A1 (en) | 2019-09-12 |
| JP6526089B2 (ja) | 2019-06-05 |
| RU2640252C2 (ru) | 2017-12-27 |
| GB2504888B (en) | 2016-02-03 |
| US20140170136A1 (en) | 2014-06-19 |
| KR20140041532A (ko) | 2014-04-04 |
| BR112013028652A2 (pt) | 2016-11-29 |
| CA2834983A1 (en) | 2012-11-15 |
| BR112013028652A8 (pt) | 2017-12-26 |
| EP2705056B1 (en) | 2018-11-14 |
| JP2014519318A (ja) | 2014-08-14 |
| CA2834983C (en) | 2020-11-17 |
| AU2012252153A8 (en) | 2013-12-19 |
| RU2013154307A (ru) | 2015-06-20 |
| SG194795A1 (en) | 2013-12-30 |
| NZ617448A (en) | 2015-01-30 |
| WO2012153123A1 (en) | 2012-11-15 |
| EP3502136A1 (en) | 2019-06-26 |
| GB201320050D0 (en) | 2013-12-25 |
| MY160884A (en) | 2017-03-31 |
| AU2012252153B2 (en) | 2016-07-07 |
| CN103764677A (zh) | 2014-04-30 |
| JP2017123870A (ja) | 2017-07-20 |
| GB2504888A (en) | 2014-02-12 |
| KR101833465B1 (ko) | 2018-02-28 |
| AU2012252153A1 (en) | 2013-11-14 |
| EP2705056A1 (en) | 2014-03-12 |
| ES2704007T3 (es) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2504887B (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
| SG10201500960TA (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| GB2504888B (en) | Anti-Nerve growth factor antibodies and methods of preparing and using the same | |
| GB201517547D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| HK1255608A1 (zh) | 抗htra1抗體及使用方法 | |
| HK1213581A1 (zh) | 抗- 抗體及其使用方法 | |
| HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
| ZA201308022B (en) | Anti-cd40 antibodies and methods of use | |
| EP2748199A4 (en) | ANTI-OX40 ANTIBODIES AND METHOD FOR THEIR USE | |
| ZA201403760B (en) | Anti-cd98 antibodies and methods of use thereof | |
| GB201223276D0 (en) | Antibodies and methods of producing same | |
| HK1201843A1 (en) | Anti-polyubiquitin antibodies and methods of use | |
| ZA201306451B (en) | Anti-il-6 receptor antibodies and methods of use | |
| EP2771694A4 (en) | MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE | |
| EP2611832A4 (en) | ANTI-CXCL13 ANTIBODIES AND METHOD FOR THEIR USE | |
| EP2663330A4 (en) | ANTIBODIES TO TLR4 AND METHOD FOR THEIR USE | |
| EP2755667A4 (en) | METHOD FOR IMPROVING PUSH AND QUANTITY OF HAIR AND HAIR | |
| SG11201400405TA (en) | Caninised antibodies and method for the production of same | |
| HK1199735A1 (en) | Caninised tumour necrosis factor antibodies and methods of using the same | |
| HUS2200012I1 (hu) | Idegi növekedési faktor elleni ellenanyagok és eljárások elõállításukra és alkalmazásukra | |
| GB201519606D0 (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same | |
| GB2505352B (en) | Anti-nerve growth factor antibodies and methods of preparing and using the same |